… In addition, the IL-1 cytokine family has a pivotal role in the induction of cytokine storm due
… COVID-19 infection. This article reviews the role of IL-1 in inflammation and utilization of IL-1 …

… ‐1 blocking agents compared with standard care alone or with placebo on effectiveness and
safety outcomes in people with COVID‐19. … on the COVID‐NMA platform ( covid-nma.com) . …

… We herein outline the contribution of immunothrombosis to COVID-19-… of COVID-19. We
also summarize current efforts to target the NLRP3 inflammasome pathway in COVID-19, and …

… differences in global outcomes of COVID-19 patients treated with IL-1 versus IL-6 … COVID-19
as well as the design of controlled investigations evaluating cytokine inhibitors in COVID-19…

… Mortality of patients with coronavirus disease 2019 (COVID-19), … Anakinra is a recombinant
interleukin-1 receptor antagonist … This study is part of the COVID-19 Biobank study, which is …

… coronavirus 2 (SARS-CoV-2) infection crucially worsens clinical evolution of coronavirus
disease 2019 (COVID-19… Evidence suggests that inflammasome activation and interleukin-1β (IL…

… ), some severe and critically ill COVID-19 patients with multiple organ … specific interleukin
(IL)-1 inhibitors, specific IL-6 inhibitors, and GM-CSF blockades in the treatment of COVID-19 (…

… IL-1 family are central mediators of the COVID-19 cytokine storm. Thus, we aim to explore
whether a genetic variation of the IL-1 family is associated with COVID-19. The acronym IL-1 …

… by coronavirus disease 2019 (COVID‐19) worldwide has exceeded 4·5 million. A subgroup
of patients with COVID‐19 … COVID‐19 and are currently being investigated in clinical trials. …

… safety and efficacy for treating severe coronavirus disease 2019 (COVID-19). Numerous
electronic … Anakinra is beneficial in lowering mortality in COVID-19 patients. However, these non-…